Nafarelin


Generic Medicine Info
Contraindications
Undiagnosed vag bleeding. Pregnancy and lactation.
Special Precautions
Patient w/ pituitary adenoma, polycystic ovarian disease, psychiatric comorbidities, risk factors for BMD, intercurrent rhinitis; history of seizures, cerebrovascular disorders, CNS anomalies or tumours. Childn. Monitoring Parameters Monitor BMD (prior to therapy and before retreatment), FSH and LH blood levels, bone age measurement, development or worsening of psychiatric symptoms, menstruation, vag bleeding/spotting.
Adverse Reactions
Significant: Ovarian cysts, risk of cystic enlargement, decreased BMD, pituitary apoplexy (e.g. sudden headache, CV collapse, vomiting, visual/mental status change); psychiatric events (e.g. emotional lability, irritability, aggression, depression), seizures, convulsions, vag bleeding, breast enlargement. Nervous: Insomnia, paraesthesia. CV: Oedema, HTN, hypotension. Resp: Rhinitis, nasal mucosal irritation. Genitourinary: Vulvovaginal dryness, vag discharge, uterine haemorrhage, ovarian hyperstimulation syndrome. Endocrine: Hot flushes, variable libido, artificial menopause, hypertriglyceridaemia, breast atrophy, hypercholesterolaemia, wt gain/loss, oestrogen deficiency. Haematologic: WBC decrease, eosinophilia. Musculoskeletal: Myalgia, arthralgia. Dermatologic: Acne vulgaris, hypertrichosis, body odor, seborrhoea, hirsutism, alopecia. Immunologic: Hypersensitivity reactions (e.g. chest pain, urticaria, pruritus, dyspnoea, rash). Others: Hyperphosphataemia, hypocalcaemia.
Drug Interactions
May enhance the effect of corifollitropin alfa.
ATC Classification
H01CA02 - nafarelin ; Belongs to the class of gonadotropin-releasing hormones. Used in hypothalamic hormone preparations.
Disclaimer: This information is independently developed by CIMS based on nafarelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in